PMC5996894. Kamradt T, Amling M, Dankbar B, Dudeck A, Gunzer M, Ignatius A, Krönke G, Kubatzky K, Pap T, Prinz I, Schett G, Schinke T, Tuckermann J, Waisman A. Mutual influence of immune system and bones

Janik MK, Zachou K, Sebode M, Schramm C, Londoño MC, Habes S; UK-AIH Consortium, Oo YH, Lalanne C, Pape S, Schubert M, Hust M, Dübel S, Thevis M, Jonigk D , Beimdiek J, Buettner FFR, Drenth JP, Muratori

S, Röbbel L, Safieddine B , Deuker JU, Hillemanns P, Ismaéel F, Moser A, Noeding K-H, Noesselt T, Pape J, Park-Simon T-W, Peschel S, Seifert W, Siggelkow W, Thoma M, Uleer C, Geyer S (2021). Prädiktoren

Qualitätssicherung 2010; 15: 251-259. Dintsios CM, Haverkamp A, Wiegand J, Gerlach T, Wedemeyer H, Pape G, Manns MP, Krauth C . Economic evaluation of early monotherapy versus delayed monotherapy or combination

modern cardiovascular science: Translator‘s notes relating to the English translation of two seminal papers. Prog Biophys Mol Biol 2014;115(2-3):154-161 Silva DS, Bourque J, Goering P, Hahlweg KA, Stergiopoulos

Applicable Range Beyond Immunosuppression Bak, Szilvia, Tischer, Sabine, Dragon, Anna, Ravens, Sarina, Pape, Lars, Koenecke, Christian, Oelke, Mathias, Blasczyk, Rainer, Maecker-Kolhoff, Britta; Eiz-Vesper

follow-up studies to evaluate the results of screening. In: Harel S (ed.): The at risk infant, selected papers from the International Workshop, Tel-Aviv, July, 23-31, 1979. Amsterdam, Oxford, Princeton: Elsevier

10.1002/eji.200737634 Originalpublikation Schulte-Baukloh,H. ; Bigalke,H. ; Miller,K. ; Heine,G. ; Pape,D. ; Lehmann,J. ; Knispel,H. H. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy